There are a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk, says Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
There are a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk, says Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
Transcript
How are social determinants of health being addressed? What is your role as a social worker to help in this area?
At Northwest Medical Specialties, we have a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk. So we screen every patient for distress. That would include practical concerns, emotional, spiritual, physical. We screen every person for depression. We also have Jvion … which is an AI [artificial intelligence] tool that helps identify people who may be at higher risk. Our case managers are constantly monitoring for hospital admission.
Along with that our authorizations department, our financial counselors are looking at insurance and cost of care and so people who may be underinsured or not insured, those are coming to the service right away.
All of these tools help us identify where people might have needs or might be struggling right off the bat. So people are going in and able to intervene right at the start.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More